TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.98

Change

0.00 (0.00)%

Market Cap

USD 1.81B

Volume

0.32M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+10.00 (+2.29%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+14.92 (+2.54%)

USD 65.38B
ARGX argenx NV ADR

-7.84 (-1.33%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+0.14 (+0.05%)

USD 32.75B
ONC BeiGene, Ltd.

-3.12 (-1.29%)

USD 27.70B
SMMT Summit Therapeutics PLC

-0.21 (-0.81%)

USD 27.07B
RPRX Royalty Pharma Plc

+0.24 (+0.74%)

USD 18.40B
INSM Insmed Inc

+0.49 (+0.73%)

USD 11.84B
INCY Incyte Corporation

+1.11 (+1.72%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

+0.56 (+0.97%)

USD 11.29B

ETFs Containing TARS

SLX VanEck Steel ETF 5.46 % 0.56 %

+1.42 (+0.00%)

N/A
BASE-B:CA Evolve Global Materials &.. 4.97 % 0.00 %

+0.29 (+0.00%)

CAD 0.08B
XME SPDR® S&P Metals and Min.. 4.86 % 0.35 %

+1.57 (+0.00%)

N/A
FXZ First Trust Materials Alp.. 4.02 % 0.64 %

+1.09 (+0.00%)

N/A
PYZ Invesco DWA Basic Materia.. 3.55 % 0.60 %

+1.95 (+0.00%)

USD 0.05B
SMLL Harbor ETF Trust 3.46 % 0.28 %

+0.44 (+0.00%)

N/A
IYM iShares U.S. Basic Materi.. 2.93 % 0.00 %

+2.39 (+0.00%)

N/A
PILL Direxion Daily Pharmaceut.. 2.54 % 0.98 %

+0.16 (+0.00%)

N/A
PICK iShares MSCI Global Metal.. 1.72 % 0.39 %

+0.24 (+0.00%)

USD 0.31B
MDYV SPDR® S&P 400 Mid Cap Va.. 1.19 % 0.15 %

+1.71 (+0.00%)

N/A
ZMID:CA BMO S&P US Mid Cap Index .. 0.57 % 0.00 %

+0.65 (+0.00%)

N/A
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.57 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.57 % 0.00 %

N/A

N/A
VBR Vanguard Small-Cap Value .. 0.49 % 0.07 %

+4.42 (+0.00%)

USD 29.21B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

+2.67 (+0.00%)

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

+1.82 (+0.00%)

N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

+1.50 (+0.00%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.30 (+0.00%)

N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

+1.96 (+0.00%)

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

+1.14 (+0.00%)

N/A
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

+0.98 (+0.00%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.38% 52% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.38% 52% F 29% F
Trailing 12 Months  
Capital Gain 22.76% 82% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.76% 82% B 79% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 23.56% 70% C- 81% B-
Dividend Return 23.56% 70% C- 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.82% 50% F 27% F
Risk Adjusted Return 34.74% 88% B+ 69% C-
Market Capitalization 1.81B 88% B+ 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector